Work

Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.4524

Authors: Asim Amin, Arkadiusz Z. Dudek, Theodore F. Logan, Raymond S. Lance, Jeffrey M. Holzbeierlein, Viraj A. Master, Sumanta Kumar Pal, Jennifer J. Knox, Lawrence Ivan Karsh, Doug Plessinger, Charles A. Nicolette, Robert A. Figlin, AGS-003-006 Study Group

Institutions: Levine Cancer Institute, University of Illinois Chicago, Indiana University, Urology of Virginia, University of Kansas, Emory University, City Of Hope National Medical Center, City of Hope, Princess Margaret Cancer Centre, The Urology Center of Colorado, Argos Therapeutics (United States), Cedars-Sinai Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599731639

Cites:

Cited by: 6

Related to: 10